Article Text
Therapeutics
Telmisartan and ramipril were equivalent, but their combination increased adverse events in vascular disease or diabetes
Statistics from Altmetric.com
Footnotes
Source of funding: Boehringer Ingelheim; Heart and Stroke Foundation of Ontario; Canadian Institutes of Health Research.